论文部分内容阅读
分析基因工程干扰素治疗慢性乙型肝炎 43例临床资料 ,结果表明血清呈 HBs Ag、HBe Ag阳性而 AL T异常者和慢性活动性肝炎者的效果较好 ,总有效率分别为 5 9.1% (13/ 2 2 )和 75 % (12 / 18) ;血清呈 HBs Ag、抗 HBe阳性而 AL T异常者 ,HBs Ag、HBe Ag或抗 HBe阳性而 AL T正常者 ,无症状乙肝病毒携带者 ,慢性迁延肝炎者 ,合并肝硬化或肝细胞癌者治疗效果较差 ,总有效率分别为 16 .7% (1/ 6 )和 0 ,0 ,2 5 % (2 / 8) ,0。提示这些因素可以作为选择干扰素治疗的参考适应症。
Analysis of genetic engineering interferon treatment of chronic hepatitis B in 43 cases of clinical data showed that serum HBsAg, HBeAg positive and ALT abnormalities and chronic active hepatitis were better, the total effective rate was 51.9% ( HBs Ag, HBeAg or anti-HBe positive and normal ALT, asymptomatic hepatitis B virus carriers, hepatitis B virus carriers, Patients with chronic persistent hepatitis had poorer outcomes in patients with cirrhosis or hepatocellular carcinoma, with a total effective rate of 16.7% (1/6) and 0,0.55% (2/8), respectively. Tip these factors can be used as a reference indication for the choice of interferon therapy.